Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

aTYR Pharma Inc (ATYR)

A forensic read on aTYR Pharma Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

F · Poor — capital at risk

Forensic grade

Distress

Financial health

-19.5

Distress distance

Forensic signals

-107.8%

ROE

-19.1%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

ATYR Pharma Inc earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -19.5, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+31.7%/yr

FY2023–FY2025

Share-count dilution. Diluted share count changed +73% over the last 2 years to FY2025 (+31.7%/yr). The count is growing — 53.6M shares in FY2023, 93.0M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~31.7% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~42%.

2630% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 2630% of revenue in FY2025 — about $0.05 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 31.7% a year across FY2023–FY2025, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.

Key fundamentals

Latest Revenue$190,000

Revenue Growth YoY-19.1%

Revenue CAGR (2yr)-26.6%

Net Margin-39009.5%

Free Cash Flow-$62.1M

Return on Equity-107.8%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from aTYR Pharma Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.